October 25, 2006

Takeda Pharmaceutical Company Limited

Takeda to Establish New Research Facility
in Fujisawa, Japan

October 25, 2006, Osaka, Japan --- Takeda Pharmaceutical Company Limited ("Takeda") today announced that it will establish new research facility in Fujisawa city, Kanagawa prefecture, integrating the current research facilities in Osaka city and Tsukuba city, Ibaragi prefecture. The new facility is planned to start the operation in fiscal year of 2010.

Under the 2006-10 Medium-Term Management Plan, Takeda is challenging to accomplish the management tasks in order to become "a world-class pharmaceutical" company with Japanese origin" based on Takeda-ism which refers to our commitment to conducting corporate activities with integrity. One of the most important management tasks for continued growth in a global scale, among those set forth in the 2006-10 Medium-Term Management Plan, is "enhancement of capability to create new drugs through in-house R&D activities". For that purpose, Takeda will reform R&D management processes and conduct investment focused on the global research infrastructure so that it will build a structure that enables continued launch of new products from its in-house R&D activities from fiscal year of 2011.

By integration and reorganization of the drug research functions currently located in Osaka city and Tsukuba city, Takeda will unify research facilities in Japan and will conduct the world-class research activities for drug research, through establishing the vigorous and dynamic research structure which attracts both internal and external researchers all over the world.

Takeda will carefully study the detailed plan of the establishment of new research facility and transfer of functions from the current facilities, by securing the cooperation and assistance of local authorities and community.

Mainly based on the enhancement of the research infrastructure as was stated above,Takeda will pursue to become a company that grows together with its shareholders and all other stakeholders by achieving its 2006-10 Medium-Term Management Plan through the realization of the management mission of "striving toward better health of individuals and progress of medicine by developing superior pharmaceutical products"

# # #